comprehensive
Previous article：
Bright Health sells Medicare Advantage business to Molina
Next article： Biotech companies concerned about China biosecurity crackdown
Next article： Biotech companies concerned about China biosecurity crackdown
focus
focus
-
Was Amgen transparent enough on FDA's concern on cancer drug?
2025-09-27 23:27
-
A Q&A with Aletha Maybank, AMA’s chief health equity officer
2025-09-27 22:37
-
ALS groups 'won't be played again' by the FDA, drug sponsors
2025-09-27 22:31
-
Kristina Burow of ARCH Venture Partners shares her next big bets STAT
2025-09-27 22:26 -
Chan Zuckerberg Biohub Chicago to focus on inflammation
2025-09-27 21:57
-
Chemotherapy drug shortage eases slightly but still widespread
2025-09-27 21:36